For patients with hormone receptor-positive, HER2-negative (HR+/HER2−) early-stage breast cancer, which accounts for approximately 70% of cases, a critical challenge is identifying those who will benefit from adjuvant chemotherapy2. This evidence concerns the gene HR and breast cancer.